Chronic Lymphocytic Leukemia

Imbruvica Found to Extend Survival in CLL Patients (06-19-2014)

Researchers reported at the annual American Society of Clinical Oncology meeting in Chicago that chronic lymphoid leukemia (CLL) patients treated with Imbruvica™ (ibrutinib) showed improved survival when compared to those treated with Arzerra® (ofatumumab).... Continue Reading

Arzerra Plus Chlorambucil Approved for Previously Untreated CLL (04-30-2014)

The U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab) in combination with chlorambucil in previously untreated patients with chronic lymphocytic leukemia (CLL)... Continue Reading

Ibrutinib approved by FDA for Chronic Lymphocytic Leukemia (02-12-2014)

On February 12, 2014, the U. S. Food and Drug Administration granted accelerated approval to ibrutinib (IMBRUVICA, Pharmacyclics, Inc.) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. ... Continue Reading

Chronic Lymphocytic Leukemia Phase III Trial Stopped After Data Shows Clear Advantage for Imbruvica (01-29-2014)

An Independent Data Monitoring Committee (IDMC) recommended that a phase 3 study be stopped early after data indicated that Imbruvica™ (ibrutinib) provided a clear survival advantage compared with the control drug in patients with chronic lymphocytic... Continue Reading

Gazyva Approved for CLL (11-22-2013)

The U.S. Food and Drug Administration (FDA) has approved Gazyva™ (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL). Chronic lymphocytic leukemia (CLL) is the most common... Continue Reading

Ibrutinib Highly Active in Patients with Chronic Lymphocytic Leukemia with 17p Deletion (07-18-2013)

The targeted agent ibrutinib produced rapid and durable control of disease in both treatment-naïve and relapsed/refractory patients with 17p deletion chronic lymphocytic leukemia, according to the results of a study presented at the 12th International... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (05-23-2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

Fludara plus Rituxan Extends Survival in CLL (04-6-2010)

Patients with untreated chronic lymphocytic leukemia experienced prolonged survival when treated with Fludara® (fludarabine) plus Rituxan® (rituximab) (delivered either concurrently or sequentially), according to the results of a study presented... Continue Reading

Rituxan Approved for Chronic Lymphocytic Leukemia (02-24-2010)

The U.S. Food and Drug Administration (FDA) has expanded the approval of Rituxan® (rituximab) to include the treatment of certain patients with chronic lymphocytic leukemia. Chronic lymphocytic leukemia (CLL) is the most common adult leukemia with... Continue Reading

Arzerra™ Approved for Refractory Chronic Lymphocytic Leukemia (10-28-2009)

The targeted therapy Arzerra™ (ofatumumab) has been granted accelerated approval by the U.S. Food and Drug Administration for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory to Fludara® (fludarabine) and Campath® (alemtuzumab). Chronic... Continue Reading

« Previous PageNext Page »